Cargando…
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
While current lymphoma therapies induce remission in most dogs, drug‐resistant relapse is common, creating a need for novel agents. Rabacfosadine (RAB), a double prodrug of the acyclic nucleotide phosphonate 9‐(2‐phosphonylmethoxyethel) guanine (PMEG), preferentially targets lymphoma cells with redu...
Autores principales: | Saba, Corey F., Clifford, Craig, Burgess, Kristine, Phillips, Brenda, Vail, David, Wright, Zachary, Curran, Katie, Fan, Timothy, Elmslie, Robyn, Post, Gerald, Thamm, Douglas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754483/ https://www.ncbi.nlm.nih.gov/pubmed/32346934 http://dx.doi.org/10.1111/vco.12605 |
Ejemplares similares
-
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
por: Thamm, D.H., et al.
Publicado: (2017) -
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
por: Cawley, Jacob R., et al.
Publicado: (2020) -
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
por: Weishaar, Kristen M., et al.
Publicado: (2021) -
Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
por: Morges, M.A., et al.
Publicado: (2014) -
Erratum for Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Publicado: (2020)